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Pediatric Medical Device Development Pathways
Summary
• The Pediatric Medical Device Safety and Improvement Act (PMDSIA) was passed in 2007 to increase
the number of pediatric devices approved by the Food and Drug Administration (FDA).
• PMDSIA also led to the introduction of the Pediatric Device Consortia grant program, which
promotes institutions to pass new pediatric devices.
• In the past, people relied on nontraditional methods of gaining capital for medical device development.
• Since the act, pediatric devices have still lagged behind FDA-approved adult medical devices due to
various clinical hurdles, including the small market size, which can result in a limited return on
investment (ROI), a challenge for private investors.
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Topic Relevance by Timeline 
Summary 
● The Pediatric Medical Device Safety and Improvement Act (PMDSIA) was passed in 2007 
to increase the number of pediatric devices approved by the Food and Drug Administration 
(FDA).  
● PMDSIA also led to the introduction of the Pediatric Device Consortia grant program, 
which promotes institutions to pass new pediatric devices. 
● In the past, people relied on nontraditional methods of gaining capital for medical device 
development.  
● Since the act, pediatric devices have still lagged behind FDA-approved adult medical de-
vices due to various clinical hurdles, including the small market size, which can result in a 
limited return on investment (ROI), a challenge for private investors.  
Introduction 
By definition, pediatric medical devices help to treat or diagnose conditions from birth to the age 
of 21. Medical device companies often steer away from products that are targeted toward pediatric 
populations—due to the small market size relative to adult populations—and from the unique 
needs of this patient group, which can result in additional costs and time for clinical trials. Thus 
there can be limited medical device treatment options for pediatric patients. To overcome these 
hurdles, several key initiatives have been launched to promote the development of pediatric med-
ical devices. These programs, the unique pediatric regulatory considerations, and other 
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opportunities/challenges will be discussed in this chapter. As with adult medical devices, applica-
tions for new pediatric devices must be reviewed by the FDA’s Center for Devices and 
Radiological Health (CDRH), and pediatric medical devices are classified into three groups: class 
I, II, and III. (see the chapter on “FDA Device Regulation: 510(k), PMA”). 
FDA Initiatives 
In 2009, the FDA began a grant program called the Pediatric Device Consortia (PDC) to promote 
the development, production, and distribution of pediatric medical devices by funding various 
nonprofits (Lai et al.). Since the launch of the program, different regional consortia have been 
funded: Atlanta, D.C., southern California, Philadelphia, Boston, and UCSF, amongst others.  
 
Previously, in 2007, Congress had passed a bill called the Pediatric Medical Device Safety and 
Improvement Act (PMDSIA), which intended to increase the number of FDA approvals for pedi-
atric devices (Jenkins et al.). The act had two parts: 1) to eliminate the profit restriction on devices 
under the Humanitarian Device Exemption (HDE) and 2) to provide grant money to nonprofit 
consortia to promote the development of pediatric devices. Before the act, companies could not 
profit from devices that were passed under HDE, i.e., high-risk devices that were approved due to 
the need for devices for rare diseases. By eliminating the profit restriction, companies had a new 
incentive to develop pediatric devices. As a result of the formation of the PDC, the consortia have 
led to the successful development of new pediatric devices.  
 
The consortia bring together individuals, groups, or institutions that work jointly to develop new 
pediatric medical devices. The consortium grants are not awarded for specific devices. Rather, 
groups work together to address the clinical needs for developing pediatric medical devices, in-
cluding the intellectual property (IP), business planning, regulatory advising, testing, and 
engineering involved (Lai et al.). The funding originates from the Office of Orphan Products 
Development, but the grant supports the development of all pediatric medical devices for both rare 
and common diseases. The FDA has awarded about $3.3 to $6 million each year to support the 
seven or eight consortia as shown in Table 1 (Office of the Commissioner). 
Clinical Need and Hurdles  
Before the act, there was little incentive for companies to develop new pediatric devices, due to 
the limited return on investment. According to the FDA, pediatric device development lags five to 
ten years behind adult device development. Oftentimes pediatric surgeons apply adult instruments 
to pediatric patients (Iqbal et al.). In some cases, these off-label uses of adult medical devices have 
led to adverse events (Hwang et al.). Additionally, when adult devices no longer maintain their 
profitability, the production is stopped even if they may have a beneficial pediatric use: for exam-
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ple, the Linvatec arthroscopy knife was discontinued despite its potential use for pediatric popula-
tions (Iqbal et al.). Even if there is an individual clinician with a novel idea, there may be difficulty 
developing a product through the entire pediatric regulatory process. Developing a medical device 
includes building a prototype and manufacturing the device for clinical use, which may require 
outsourcing and can be costly (Iqbal et al.). The device must then be tested in vivo and in animal 
studies before the inventor or clinician can proceed to an investigational device exemption (IDE). 
Iqbal et al.’s 3MP IDE was 141 pages and took more than a decade to write. Thus, the medical 
device pathway is time-consuming and costly. The long regulatory pathway is specific to the U.S.; 
in comparison, the process of obtaining the Conformité Européenne (CE) mark requires simply 
that the investigator demonstrate that the device performs its stated function and is safe (Iqbal et 
al.). In Europe, investigators do not need to show randomized trial data, which is one of the regu-
latory hurdles in the U.S.  
 
Table 1. PDC Funding from 2013 to 2017.  
 
 
 
The main problem in the pediatric medical device industry is that there may not be enough support 
for inventors to see their product become approved and benefit society. The underlying issue with 
pediatric devices is that they serve a limited population, thus oftentimes many pediatric medical 
devices are categorized as orphan devices (Iqbal et al.). Companies may not want to treat diseases 
with low prevalence rates, due to the small return on investment and the negative press stemming 
from the price of treatment (Iqbal et al.). For example, Genzyme Corporation made a product to 
treat Gaucher’s disease that cost $400,000 per patient annually. The patient size was 20,000 people 
in the U.S., which caused controversy for the company, as it was criticized for price gouging (Iqbal 
et al.).  
 
In some cases, a company may choose to develop and produce a pediatric device out of altruism, 
and it may not bring a significant profit. For example, Covidien produced a uterine stapling device 
in 1984 to support the advent of open fetal surgery. Covidien still manufactures the product despite 
its limited profitability, in order to continue to support fetal surgeons (Iqbal et al.). Similarly, Karl-
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Storz occasionally stops the manufacturing of its profitable adult line of surgical instruments in 
order to produce 3mm endoscopic instruments for pediatric surgeons (Iqbal et al.). Only 5%–6% 
of healthcare is actually spent on children, despite the fact that about 25% of the population are 
children, in large part due to the fact that most children are healthy. Thus, a specific device may 
only target a fraction of that 5%–6%, which makes pediatric devices potentially unprofitable 
(Barbella).  
 
An illustrative example involves a businessman named Tim Moran, who took matters into his own 
hands when he faced difficulty finding support for medical devices for premature infants. Moran 
formed a nonprofit called PediaWorks Inc. at the Cleveland Clinic’s business development center. 
He was personally motivated by his eldest child’s premature birth and the lack of devices available 
for neonates. One vivid incident involved the distress his daughter experienced as the doctors 
strapped an extremely large airway mask to her head because it was the only one available. While 
Moran was experienced with the business side of his pediatric device company, no one was inter-
ested in investing, because, he was told, “it’s not a market that we can justify to our shareholders” 
(Barbella). Moran was determined and ended up cold-calling a Japanese medical equipment firm, 
which ultimately invested $500,000 into his venture, and he was able to successfully develop 
pediatric catheters and sheaths. Moran’s experience is a common one—companies or 
organizations interested in pediatric device development have had to rely on nontraditional 
financing based on “purpose rather than profit” (Barbella).  
 
While the PDC has aimed to close the gap between clinical needs and the availability of pediatric 
devices, there remains considerable work to be accomplished. The PDC should continue to expand 
its consortia to other cities. One current limitation of the grant is that the institution must already 
have a well-established infrastructure for device development that includes clinical, scientific, and 
business arms (Iqbal et al.). However, there must also be greater capital investment beyond the 
PDC. That is, there needs to be a paradigm shift in the way the pediatric device world generates 
profit, and this would start with investors. Successful pediatric devices have often been funded by 
altruism or personal investment in a device. There needs to be more support for orphan devices 
that go beyond altruism and personal investment, although this would certainly be a long-term 
issue that requires time to resolve. Other solutions would be further government initiatives to pro-
mote industry involvement, in the form of grants or tax incentives (Iqbal et al.). Additionally, more 
programs can be created that focus on device innovation within medical and business schools, 
which may include training on IP and regulatory pathways (see the chapters “Intellectual Property: 
Ownership and Protection in a University Setting” and “Intellectual Property: Commercializing in 
a University Setting”).  
 
Another concern regarding the 2007 PMDSIA Act is that it has not led to as much innovation as 
expected for pediatric patients under the age of 18. In a 2014 study by Hwang et al., almost all the 
high-risk devices approved were indicated for pediatric patients above the age of 18. The devices 
were approved on the basis of a study with a small age range of patients (for 18- to 21-year-olds), 
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who are not normally considered pediatric (Hwang et al.). Thus the testing and approval of high-
risk medical devices in pediatric populations under 18 is still uncommon, even after the passage 
of the 2007 act. 
The Future of Medical Devices  
While there are certainly regulatory hurdles that have set back medical device development, there 
is hope for a faster and more efficient regulatory process, which may ultimately lead to new pedi-
atric devices. As recently as April 2018, FDA Commissioner Scott Gottlieb released a statement 
on the FDA’s new efforts to modernize the medical device pathway (Gottlieb). Gottlieb announced 
the Medical Device Safety Action Plan, which outlined the FDA’s efforts to update the regulatory 
process to help address unmet needs. One aspect of the action plan was the transition to a Total 
Product Life Cycle (TPLC) approach for product safety. TPLC is a database of pre- and post-
market information, which the FDA will use to optimize decision-making (Gottlieb). The FDA 
also announced new programs and changes that include a revamped 510(k) pathway for efficient 
approval, as well as initiatives to address unmet medical needs (see the chapters “FDA Device 
Regulation: 510(k), PMA” and “Identifying Unmet Needs: Problems that Need Solutions”). While 
the recent announcement is hopeful, it will take time for the changes to be well studied and imple-
mented. 
Conclusion 
Pediatric medical device development is challenging on several levels. Many previously approved 
pediatric devices have been developed through nontraditional methods of investment capital or 
because of individuals’ and companies’ altruism. The FDA has recently recognized this issue and 
has made progress toward modernizing the pediatric medical device pathway as well as continuing 
support for pediatric medical device development. This has created unique opportunities in terms 
of funding support and other modes of assistance that can allow for increased pediatric medical 
device development.  
Resources 
1. The list of different Pediatric Device Consortia are available on the FDA’s website: 
https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/Pediatri
cDeviceConsortiaGrantsProgram/.  
2. An introduction into the PMDSIA and its impact are summarized here: 
http://pediatrics.aappublications.org/content/early/2016/12/22/peds.2016-3439.  
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